|
Crohn Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Two SNPs (rs2241880 and rs6754677) in the ATG16L1 gene were significantly associated with the onset of CD in the Malaysian population.
|
31654602 |
2020 |
|
Crohn Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
One of those four patients was homozygous for the ATG16L1 Crohn's disease-associated gene variant but had no history of inflammatory bowel disease.
|
31692018 |
2020 |
|
Inflammatory Bowel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
One of those four patients was homozygous for the ATG16L1 Crohn's disease-associated gene variant but had no history of inflammatory bowel disease.
|
31692018 |
2020 |
|
Inflammatory Bowel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
SNPs rs1800896, rs3024505 (IL-10); rs11209026 (IL23R); rs2066844, rs2066845 (NOD-2), and rs2241880 (ATG16L1) were assessed in 93 patients with IBD and 200 healthy controls by hybridization probes and quantitative PCR.
|
31651650 |
2020 |
|
Crohn Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In patients, the CD-associated ATG16L1 T300A single-nucleotide polymorphism did not attenuate azathioprine induction of autophagy.
|
30889246 |
2019 |
|
Crohn Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Interestingly, ATG16L1 has a single homolog, ATG16L2, which is independently implicated in diseases, including Crohn disease and systemic lupus erythematosus.
|
31451676 |
2019 |
|
Crohn Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ATG16L1 polymorphisms have been linked to the development of Crohn's disease (CD), and phosphorylation of CD-associated ATG16L1 T300A (caATG16L1) has been hypothesized to contribute to cleavage and autophagy dysfunction.
|
31267703 |
2019 |
|
Crohn Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Antichitobioside was positive in 28% of patients with CD carrying the ATG16L1 A300T variant (either heterozygote or homozygote) compared with only 3% in those without the variant (P < 0.001).
|
30265311 |
2019 |
|
Crohn Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here we report an integrative analysis of an expanded number of Crohn's disease (CD) related genetic defects in innate immune function (NOD2, ATG16L1, IRGM, CARD9, XBP1, ORMDL3) and composition of the ileal microbiome by combining the initial patient cohort (Batch 1, 2005-2010, n = 165) with a second consecutive patient cohort (Batch 2, 2010-2012, n = 118).
|
30818349 |
2019 |
|
Inflammatory Bowel Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
<b>Abbreviations:</b> ATG16L1: autophagy-related 16-like 1 (S. cerevisiae); DAMP: damage-associated molecular pattern; HBSS: Hanks balanced salt solution; HMGB1: high mobility group box 1; IBD: inflammatory bowel disease; IL1B/Il-1β: interleukin 1 beta; IL10: interleukin 10; IL17/IL-17: interleukin 17; MEFs: mouse embryonic fibroblasts; STAT3: signal transducer and activator of transcription 3; TLR: toll-like receptor; TNF/TNF-α: tumor necrosis factor.
|
30894054 |
2019 |
|
Inflammatory Bowel Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Loss of A20 and Atg16l1 in mouse intestinal epithelium induces spontaneous IBD-like pathology, as characterized by severe inflammation and increased intestinal epithelial cell death in both small and large intestine.
|
31015422 |
2019 |
|
Inflammatory Bowel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We evaluated the impact of variations in ATG16L1 and NOD2 and genes on serologic responses in patients with inflammatory bowel disease (IBD).
|
30265311 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.110 |
Biomarker
|
disease |
BEFREE |
Interestingly, ATG16L1 has a single homolog, ATG16L2, which is independently implicated in diseases, including Crohn disease and systemic lupus erythematosus.
|
31451676 |
2019 |
|
Bilirubin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Bilirubin and risk of ischemic heart disease in Korea: a two-sample Mendelian randomization study.
|
31319653 |
2019 |
|
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Most importantly, we find in multiple tumor types that ATG5 somatic mutations and alternative mRNA splicing specifically disrupt the ATG16L1-binding pocket in ATG5 and impair the essential ATG5-ATG16L1 interactions that are initially required for ATG12-ATG5 conjugation.
|
31636955 |
2019 |
|
Liver carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
We found ATG5 rs17067724 (G vs A: OR = 0.80; 95% CI = 0.65-0.98; P = 0.031), ATG10 rs1864183 (G vs A: OR = 1.29; 95% CI = 1.07-1.57; P = 0.009), ATG10 rs10514231 (C vs T: OR = 1.41; 95% CI = 1.15-1.73; P = 0.001), ATG12 rs26537 (C vs T: OR = 1.16; 95% CI = 1.02-1.33; P = 0.030), and ATG16L1 rs4663402 (T vs A: OR = 1.28; 95% CI = 1.01-1.63; P = 0.044) were significantly associated with HCC risk.
|
31340167 |
2019 |
|
Liver carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The common germ-line ATG16L1 gene variant is a risk factor for HCC in patients with cirrhosis.
|
31484215 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Mechanistically, we found that BIRC5 negatively modulates the protein stability of ATG7 and physically binds to the ATG12-ATG5 conjugate, preventing the formation of the ATG12-ATG5-ATG16L1 protein complex in human cancer (MDA-MB-231, MCF7, and A549) and mouse embryonic fibroblast (MEF) cells.
|
31612776 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Knockdown of the autophagy regulatory, ATG16L1, re-sensitized lung cancer cells to cancer therapies following TGF-β-induced resistance, implicating autophagy as a TGF-β-mediated chemoresistance mechanism.
|
30736412 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Mechanistically, we found that BIRC5 negatively modulates the protein stability of ATG7 and physically binds to the ATG12-ATG5 conjugate, preventing the formation of the ATG12-ATG5-ATG16L1 protein complex in human cancer (MDA-MB-231, MCF7, and A549) and mouse embryonic fibroblast (MEF) cells.
|
31612776 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Knockdown of the autophagy regulatory, ATG16L1, re-sensitized lung cancer cells to cancer therapies following TGF-β-induced resistance, implicating autophagy as a TGF-β-mediated chemoresistance mechanism.
|
30736412 |
2019 |
|
Rheumatoid Arthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Abbreviations: 3-MA: 3-methylademine; ACTB/β-actin: actin, beta; ATG: autophagy related; ATG16L1: autophagy related 16-like 1 (S. cerevisiae); BECN1: beclin 1, autophagy related; CNR2: cannabinoid receptor 2 (macrophage); CNS: central nervous system; CQ: chloroquine; EAE: experimental autoimmune encephalomyelitis; FOXO3: forkhead box O3; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; H&E: hematoxylin and eosin; ITGAM: integrin alpha M; LPS: lipoplysaccharide; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; miRNAs: microRNAs; MS: multiple sclerosis; PPARG: peroxisome proliferator activated receptor gamma; PTPRC: protein tyrosine phosphatase, receptor type, C; RA: rheumatoid arthritis; SQSTM1: sequestosome 1; TB: tuberculosis; TIMM23: translocase of inner mitochondrial membrane 23; TLR: toll-like receptor.
|
30208760 |
2019 |
|
Tuberculosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results indicate that MtbDNA induced phenotypical changes, the significant production of TNF-α, and autophagy confirmed by the augmented expression of immunity related GTPase M (IRGM) and autophagy related ATG16L1 genes in M1 macrophages, whereas M2 macrophages exhibited limited responses.
|
31054870 |
2019 |
|
Tuberculosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Abbreviations: 3-MA: 3-methylademine; ACTB/β-actin: actin, beta; ATG: autophagy related; ATG16L1: autophagy related 16-like 1 (S. cerevisiae); BECN1: beclin 1, autophagy related; CNR2: cannabinoid receptor 2 (macrophage); CNS: central nervous system; CQ: chloroquine; EAE: experimental autoimmune encephalomyelitis; FOXO3: forkhead box O3; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; H&E: hematoxylin and eosin; ITGAM: integrin alpha M; LPS: lipoplysaccharide; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; miRNAs: microRNAs; MS: multiple sclerosis; PPARG: peroxisome proliferator activated receptor gamma; PTPRC: protein tyrosine phosphatase, receptor type, C; RA: rheumatoid arthritis; SQSTM1: sequestosome 1; TB: tuberculosis; TIMM23: translocase of inner mitochondrial membrane 23; TLR: toll-like receptor.
|
30208760 |
2019 |
|
Recurrent urinary tract infection
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Together, our results reveal that UPEC selectively utilize genes important for autophagosome formation to persist in the urothelium, and that the presence of the T300A variant in ATG16L1 is associated with changes in urothelial vesicle trafficking, which disrupts the ability of UPEC to persist, thereby limiting the risk of recurrent UTIs.
|
30335568 |
2019 |